74126-25-3

Basic information

• Product Name: H-D-TRP-OET.HCL
• Synonyms: (R)-Tryptophan ethyl ester;H-D-TRP-OET HCL
• CAS NO: 74126-25-3
• Molecular Formula: C₁₃H₁₆N₂O₂
• Molecular Weight: 232.281
• Mol File: 74126-25-3.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: H-D-TRP-OET.HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-TRP-OET.HCL(74126-25-3)
• EPA Substance Registry System: H-D-TRP-OET.HCL(74126-25-3)

Safety Data

• Hazardous Substances Data: 74126-25-3(Hazardous Substances Data)

Usage

General Description

H-D-TRP-OET.HCL is a chemical compound with the molecular formula C16H20ClNO4. It is a derivative of the amino acid tryptophan and contains an ethyl ester group. H-D-TRP-OET.HCL is typically used in research and pharmaceutical studies as a building block for the synthesis of various peptides and proteins. It is commonly used as a component in drug development and in the study of neurochemistry and neurotransmitter functions. H-D-TRP-OET.HCL is a valuable tool for investigating the structure and function of biological molecules and has potential applications in the development of new therapeutics for various diseases and conditions.

Upstream product

• 64-17-5 ethanol 
• 153-94-6 D-tryptophan 
• 15142-91-3 rac-3-(1H-indol-3-yl)-2-methylpropanoic acid 
• 54-12-6 Trp 
• 101427-38-7 2,2'-dinitro-2,2'-(2-aza-propanediyl)-di-malonic acid tetraethyl ester 
• 120-72-9 indole 
• 63971-99-3 ethyl 3-(1H-indol-3-yl)-2-nitropropanoate 
• 125109-04-8 ethyl α-(hydroxyimino)-β-(N-methylindol-3-yl)propanoate 

Downstream Products

• 42717-06-6 acetyltryptophan ethylester 
• 84518-77-4 ethyl 1,2,3,4-tetrahydro-β-carboline-3-carboxylate 
• 7479-05-2 L-tryptophan ethyl ester 
• 475101-82-7 N^α-(3-phenylpropionyl)tryptophan 
• 374710-96-0 1-phenyl-9H-pyrido [3,4-b]indole-3-carboxylic acid 

Relevant articles and documents

Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy

Overexpression of histone deacetylases (HDACs) are observed in different types of cancers, but histone deacetylase inhibitors (HDACIs) have not shown significant efficacy as monotherapy against solid tumors. Recently, studies demonstrated that it is promi

A class of DL-tryptophan compounds, preparation method and applications thereof

The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.

Biological evaluation and structure activity relationship of 9-methyl-1-phenyl-9H-pyrido[3,4-b]indole derivatives as anti-leishmanial agents

A series of piperazinyl-β-carboline-3-carboxamide derivatives were designed through a molecular hybridization approach. Designed analogues were synthesized, characterized and evaluated for anti-leishmanial activity against Leishmania infantum and Leishmania donovani. In L. infantum inhibition assay, compounds 7d, 7g and 7c displayed potent inhibition of promastigotes (EC50 1.59, 1.47 and 3.73 μM respectively) and amastigotes (EC50 1.4, 1.9 and 2.6 μM respectively). SAR studies revealed that, para substitution of methoxy, chloro groups and methyl group on ortho position favored anti-leishmanial activity against L. infantum. Among these analogues 7d, 7h, 7n and 7g exhibited potent inhibition against L. donovani promastigotes (EC50 0.91, 4.0, 4.57 and 5.02 μM respectively), axenic amastigotes (EC50 0.9, 3.5, 2.2 and 3.8 μM respectively) and intracellular amastigotes (EC50 1.3, 7.8, 5.6 and 6.3 μM respectively). SAR studies suggested that, para substitution of methoxy group, para and meta substitution of chloro groups and benzyl replacement recommended for significant anti-leishmanial against L. donovani.